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1. Introduction 
Amidst a worldwide epidemic of diabetes, the World Health Organization estimates that 
346 million people have diabetes and an estimated 3.4 million people died from 
consequences of high blood sugar in 20041). Over time, diabetes can damage the heart, blood 
vessels, eyes, kidneys, and nerves. Especially diabetes increases the risk of heart disease and 
stroke. 
Obesity carries with it significant risks of diabetes. Improvement in obesity is attendant 
with improvements in this ailment2)3), and obese people consequently have been treated 
through pharmacotherapy, and intervention in life habits, including diet and exercise. 
Even with such treatment, however, it is very difficult to have satisfactory body weight 
loss. In the last few years, many studies have performed to compare intensive glucose 
control therapy with standard therapy. Most of the results show that body weight did not 
change with both intensive glucose control therapy and standard therapy4)5). Moreover, 
many patients who are initially successful at weight loss then go on to rebound6). Thus, 
promoting weight loss is a major issue in treatment, especially in severely obese patients. 
Recently, there has been an increase in patients with a BMI > 35 undergoing bariatric 
surgery and there has been a notable increase in studies describing effect of bariatric 
surgery on type 2 diabetes patients6). 
2. Effect of bariatric surgery on obesity and diabetes 
Although an average of 55.9% loss in excess body weight was observed in bariatric 
surgery6), the extent of operation-induced weight loss varies depending on the surgical 
method7). While loss in body weight from intervention in life habits is insufficient, it was 
46.2% for gastric binding and 59.5% for gastric bypass, respectively, thus showing that 
bariatric surgery leads to more efficient weight-loss results6). However, although bariatric 
surgery generally leads to a great improvement in diabetes8) (Table 1), there is a gradation of 
results depending on the procedure9). Additionally for type 2 diabetes patients, studies on 
gastric bypass have shown that improvements in fasting plasma glucose and insulin 
sensitivity are evident prior to weight loss10)11). These kinds of changes are not observed in 
gastric binding6)12). From these results, apart from improvements in insulin sensitivity 
induced through weight loss, gastric bypass is also thought to improve glucose metabolism. 
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 Total (n) Gastric Binding (n) Gastric Bypass (n) 
Absolute Weight Loss (Kg) 
BMI Decrease (kg/m2) 
Excess Loss (%) 
Fasting Insulin (pmol/L) 
HbA1c (%) 
Fasting Glucose (mmol/L) 
-41.9 (266) 
-14.0 (306) 
-57.3 (267) 
-123.9 (160) 
-2.4 (171) 
-4.0 (296) 
-26.0 (56) 
-9.1 (56) 
-41.0 (83) 
-49.5 (56) 
-1.2 (83) 
-3.2 (56) 
-50.54 (129) 
-18.0 (166) 
-65.7 (184) 
-153.7 (90) 
-3.0 (88) 
-3.4 (164) 
BMI: body mass index    
Table 1. Efficacy for Improvement in Diabetes-Related Outcomes for Diabetic and Glucose-
Intolerant Patients 8). 
 
Incretin Secretion Function Change after  
bariatric surgery 
GLP-1 Distal ileum , 
Colon 
Increase insulin release 
Slowing gastric emptying 
Controlling Glucagon secretion  
Induce satiety by working on the central 
nervous system 
Increase 
Ghrelin Stomach Stimulate appetite 
Increasing activity in the stomach 
Suppression of insulin secretion 
Increase growth hormone secretion 
Decrease 
(Roux-en-Y 
Gastric Bypass) 
Table 2. Summary of Intestin. 
3. Effects of bariatric surgery on intestine hormone 
One hypothesis to explain this phenomenon is the influence of gastrointestinal hormones. 
Glucagon-like peptide-1 (GLP-1), an intestinal hormone secreted from the distal ileum and 
colon in response to nutrient ingestion9). GLP-1 acts on the beta cells to increase the level of 
cyclic AMP, leading to replenishment of the readily releasable pool of insulin granules 
during glucose-stimulated insulin secretion13). Not only improving beta-cell function, GLP-1 
is also involved in the proliferation and regeneration of pancreatic β-cells14)15). Outside 
pancreatic effects, GLP-1 decreases dietary intake by slowing gastric emptying16), controlling 
secretion of gastric acid17) and glucagon18), and induce satiety by working on the central 
nervous system19)20)). There have been numerous studies detailing a post-operative increase 
in GLP-1 secretion from gastric bypass, and this increase occurs prior to post-gastric bypass 
weight loss21-24). Studies show that the post-gastric bypass GLP-1 level is significantly higher 
when compared to the post-gastric binding GLP-1 level25) 26). When considering the effect of 
GLP-1, it is possible that the increase in endogenous GLP-1 secretion plays an important role 
in the improvement of glucose metabolism by the gastric bypass surgery. 
Although ghrelin is similar to GLP-1 in that it is related to the appetite, it is actually an 
appetite-stimulating hormone27-29). It is likely that the appetite stimulating from ghrelin is 
due to its increasing activity in the stomach28)30) and suppressing of insulin secretion30). 
Ghrelin levels increase in dietary restriction-induced weight loss and when there is a 
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negative energy balance, and conversely, decrease when eating or in the case of the 
obese31)32). However in the case of the obese, ghrelin levels become unchanged even when 
eating, and therefore, ghrelin level is a potential factor in obesity33). There are many reports 
demonstrating that fasting ghrelin levels decrease after Roux-en-Y Gastric Bypass compared 
to pre-operation34)35). It has been reported that decrease in ghrelin levels occurs immediately 
following surgery and lasts for more than a year36) 37). Through Roux-en-Y Gastric Bypass, 
food bypasses the distal stomach in which ghrelin is released, and this may account for the 
post-bypass decrease in ghrelin levels34).  
4. Incretin-therapy on type 2 diabetes patients 
Recently GLP-1 analog/receptor agonists and GLP-1 degradation inhibitors are in clinical 
use. The beneficial points of these antidiabetes agents are glucose-dependent 
insulinotropism which may be reduced the risk of hypoglycemia38). Liraglutide is a GLP-1 
analog with 97% sequence identity to human hormone. The mean reduction in HbA1c by 
liraglutide (1.8mg) was 1.14%39). In addition to effective glucose lowering, liraglutide 
produced beneficial effects on body weight. The mean reduction in body weight after 
16weeks treatment of 1.8mg liraglutide was 3.6kg and was sustained thoughout the 52 week 
study39). These results support the hypothesis that the bariatric surgery leads to a great 
improvement of diabetes not only by the reduction of the storage capacity of the stomach 
but also by the change in intestinal hormone. 
5. Clinical application of bariatric surgery in Asia 
As previously stated, there are reports that bariatric surgery leads to dramatic improvement 
in type 2 diabetes compared to pharmacotherapy and lifestyle intervention-based treatment. 
Will bariatric surgery replace conventional medication and/or life style intervention-based 
treatment in Asia? At present, however, most of these reports are not necessarily targeting 
regular subjects, given the subjects’ extremely high average BMI of 47.9 kg/m2 and 
relatively young average age of 40.2 years old6). 
Obesity in the Asian population is much less than in Western populations. The Ministry of 
Health, Labour and Welfare, Japan reported that only 3.7% of the population is obese 
(BMI>30)40). The rate of obesity in diabetes is reported to be similar to that in the rest of the 
Japanese population41), and at present bariatric surgery has only a limited application in 
Japan. To increase the application of bariatric surgery in Asia, there is a need for a high-
evidence level cohort study based on previous research that varies by age and obesity level 
in order to further the discussion on whether bariatric surgery should be given precedence 
over conventional medication and life style intervention-based treatment in patients with a 
BMI > 35. 
6. Summary 
Recently, in certain countries, there has been an increase in obese patients undergoing 
bariatric surgery which leads to more efficient weight-loss results. Bariatric surgery is an 
effective treatment option for severely obese patients for whom weight loss has been 
problematic with conventional pharmacotherapy and/or life style intervention-based 
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treatment. Gastric bypass has been shown not only to decrease body weight but to have an 
effect on incretin (Table2). Change in incretin, especially GLP-1, could support the 
improvement in body weight. GLP-1 also has beneficially affect on pancreatic β-cells 
function, proliferation and regeneration. Thus even if diabetes did not cure by bariatric 
surgery, change in incretin have beneficially effect on diabetes. Therefore to choose the 
operative procedure of bariatric surgery, especially on patients who have basic disease, it is 
necessary to think about dynamic state of incretin. 
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